Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A

Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.

Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #297)

J Clin Oncol 37, 2019 (suppl; abstr 7543)

Author(s): Deepa Jagadeesh, Steven M. Horwitz, Nancy L. Bartlett, Ranjana H. Advani, Eric D. Jacobsen, Madeleine Duvic, Ashish Gautam, Shangbang Rao, Matthew Onsum, Michelle Fanale, Youn H. Kim; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine in St. Louis and Siteman Cancer Center, St. Louis, MO; Stanford Cancer Institute, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Seattle Genetics Inc, Bothell, WA; Seattle Genetics, Bothell, WA; Seattle Genetics, Inc, Bothell, WA; Department of Dermatology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA

Abstract Disclosures


Background: Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, has been evaluated in multiple trials in patients (pts) with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell lymphoma. We examined the ability of CD30 expression level to predict response to BV across these patient populations. Methods: Data were integrated from 275 pts with PTCL, CTCL, and B-cell lymphoma treated with BV from 5 prospective clinical trials. Study SGN35-012 evaluated BV plus rituximab or BV monotherapy in pts with relapsed/refractory non-Hodgkin lymphoma. The ALCANZA study compared BV to physician’s choice of methotrexate or bexarotene in pts with mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL). Three investigator-sponsored trials evaluated BV monotherapy in pts with relapsed PTCL, MF, and pcALCL (35-IST-030, 35-IST-001, 35-IST-002). Exploratory analyses were conducted to examine the relationship between CD30 expression and objective response rate (ORR) for pts with CD30 expression ≥10%, <10%, or undetectable (0%) by IHC (malignant cells or lymphoid infiltrate; local review). Results: 143 pts had tumors with CD30 <10%, including 58/143 with undetectable CD30. Activity with BV was observed at all levels of CD30 expression, including CD30=0 (Table). Analysis of the interaction between CD30 and duration of response is ongoing and will be presented in the final poster. ORR by CD30 expression, n/N (%). Clinical trial information: NCT01421667, NCT02588651, NCT01578499, NCT01352520, NCT01396070Conclusions: CD30 expression levels ≥10%, <10%, or undetectable did not predict response to BV in a range of CD30-expressing lymphomas: Clinical responses occurred in pts with CD30 low and CD30 undetectable lymphomas. Limitations of IHC, the dynamic nature and heterogeneity of cell-surface CD30 expression, and multiple mechanisms of action of BV may all contribute to this observation.

PTCLSGN35-01210/22 (45)4/12 (33)2/6 (33)
35-IST-030*NA4/6 (67)1/2 (50)
CTCL (MF)ALCANZA20/28 (71)12/22 (55)NA
35-IST-00111/20 (55)11/20 (55)NA
35-IST-00212/15 (80)9/17 (53)NA
B-cell lymphomaSGN35-01217/47 (37)24/66 (36)17/50 (34)

NA=not applicable *interim analysis of non-registrational study

Other Abstracts in this Sub-Category:


1. First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 7503 First Author: Norbert Shmitz
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma


2. Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).

Meeting: 2019 ASCO Annual Meeting Abstract No: 7504 First Author: Rong Tao
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma


3. Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 7505 First Author: Catherine Diefenbach
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma